Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies

References

• Lucafò M, Franca R, Selvestrel D, et al. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opin Drug Metab Toxicol. 2018;14(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996;15(1):17–30.
   PubMed Web of Science ®Google Scholar
• Lee D, Szumlanski C, Houtman J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos. 1995;23(3):398.
   PubMedGoogle Scholar
• Asadov C, Aliyeva G, Mustafayeva K. Thiopurine S-methyltransferase as a pharmacogenetic biomarker: Significance of testing and review of major methods. Cardiovasc Hematol Agents Med Chem. 2017;15(1):23–30.
   PubMedGoogle Scholar
• Chadli Z, Kerkeni E, Hannachi I, et al. Distribution of genetic polymorphisms of genes implicated in thiopurine drugs metabolism. Ther Drug Monit. 2018;40(5):5.
   Google Scholar
• Franca R, Rebora P, Bertorello N, et al. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. The Pharmacogenomics J. 2017;17(1):4–10.
   PubMedGoogle Scholar
• Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14(7):7.
   Google Scholar
• Oliveira E, Quental S, Alves S, et al. Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur J Clin Pharmacol. 2007;63(7):703–706.
   PubMed Web of Science ®Google Scholar
• Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77(4):704–714.
   PubMed Web of Science ®Google Scholar
• Tai HL, Krynetski EY, Schuetz EG, et al. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A. 1997;94(12):6444–6449.
   PubMed Web of Science ®Google Scholar
• de la Moureyre CS-V, Debuysère H, Fazio F, et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics. 1999;9:2.
   Google Scholar
• Zukic B, Radmilovic M, Stojiljkovic M, et al. Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics. 2010;11(4):547–557.
   PubMed Web of Science ®Google Scholar
• Urbančič D, Šmid A, Stocco G, et al. Novel motif of variable number of tandem repeats in TPMT promoter region and evolutionary association of variable number of tandem repeats with TPMT*3 alleles. Pharmacogenomics. 2018;19(17):1311–1322.
   PubMedGoogle Scholar
• Alves S, Amorim A, Ferreira F, et al. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther. 2001;70(2):165–174.
   PubMed Web of Science ®Google Scholar
• Kotur N, Stankovic B, Kassela K, et al. 6-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner. Pharmacogenomics. 2012;13(3):283–295.
   PubMed Web of Science ®Google Scholar
• Wu H, Horton JR, Battaile K, et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins. 2007;67(1):198–208.
   PubMedGoogle Scholar
• Peng Y, Feng Q, Wilk D, et al. Structural basis of substrate recognition in thiopurine s-methyltransferase. Biochemistry. 2008;47(23):6216–6225.
   PubMedGoogle Scholar
• Hartford C, Vasquez E, Schwab M, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 2007;67(10):4965.
   PubMed Web of Science ®Google Scholar
• Urbančič D, Kotar A, Šmid A, et al. Methylation of selenocysteine catalysed by thiopurine S-methyltransferase. Biochim Biophys Acta Gen Subj. 2019;1863(1): 182–190.
   PubMedGoogle Scholar
• Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: molecular pathways and physiological roles. Physiol Rev. 2014;94(3):739–777.
   PubMed Web of Science ®Google Scholar
• Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science. 2003;300(5624):1439.
   PubMed Web of Science ®Google Scholar
• Hariharan S, Dharmaraj S. Selenium and selenoproteins: it’s role in regulation of inflammation. Inflammopharmacology. 2020;28(3):667–695.
   PubMed Web of Science ®Google Scholar
• Arnér ESJ. Selenoproteins—What unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res. 2010;316(8):1296–1303.
   PubMed Web of Science ®Google Scholar
• Deininger M, Szumlanski CL, Otterness DM, et al. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol. 1994;48(11):2135–2138.
   PubMedGoogle Scholar
• Ranjard L, Nazaret S, Cournoyer B. Freshwater bacteria can methylate selenium through the thiopurine methyltransferase pathway. Appl Environ Microbiol. 2003;69(7):3784–3790.
   PubMed Web of Science ®Google Scholar
• Ranjard L, Prigent-Combaret C, Nazaret S, et al. Methylation of inorganic and organic selenium by the bacterial thiopurine methyltransferase. J Bacteriol. 2002;184(11):3146–3149.
   PubMedGoogle Scholar
• Favre-Bonté S, Ranjard L, Champier L, et al. Distribution and genetic diversity of bacterial thiopurine methyltransferases in soils emitting dimethyl selenide. Biochimie. 2006;88(11):1573–1581.
   PubMedGoogle Scholar
• Fukumoto Y, Yamada H, Matsuhashi K, et al. Production of a urinary selenium metabolite, trimethylselenonium, by thiopurine S-Methyltransferase and indolethylamine N-methyltransferase. Chem Res Toxicol. 2020;33(9):2467–2474.
   PubMedGoogle Scholar
• Eklund BI, Moberg M, Bergquist J, et al. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol. 2006;70(2):747.
   PubMed Web of Science ®Google Scholar
• Franca R, Zudeh G, Pagarin S, et al. Pharmacogenetics of thiopurines. Cancer Drug Resist. 2019;2(2):256–270.
   Google Scholar
• Cara C, Peña AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: Towards a new paradigm in clinical practice. Med Sci Monit. 2004;10(11):RA247–54.
   PubMed Web of Science ®Google Scholar
• Shin J-Y, Wey M, Umutesi HG, et al. Thiopurine prodrugs mediate immunosuppressive effects by interfering with rac1 protein function. J Biol Chem. 2016;291(26):13699–13714.
   PubMed Web of Science ®Google Scholar
• Jharap B, De Boer N, Vos R, et al. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. Br J Pharmacol. 2011;163(4):722–731.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal Clin Invest. 2003;111(8):1133–1145.
   PubMed Web of Science ®Google Scholar
• Melachuri S, Gandrud L, Bostrom B. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(6):1003–1006.
   PubMedGoogle Scholar
• Karim H, Ghalali A, Lafolie P, et al. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells. Biochem Biophys Res Commun. 2013;437(2):280–286.
   PubMed Web of Science ®Google Scholar
• Adam De Beaumais T, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol. 2011;71(4):575–584.
   PubMed Web of Science ®Google Scholar
• Massimino M, Stella S, Tirro E, et al. ABL1-directed inhibitors for CML: Efficacy, resistance and future perspectives. Anticancer Res. 2020;40(5):2457–2465.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Gammal RS, Whirl-Carrillo M, et al. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm. 2016;73(23):1977–1985.
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387–391.
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013;93(4):324–325.
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5): 1095–1105.
   PubMed Web of Science ®Google Scholar
• Coenen M, Jong D, van Marrewijk C, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907-17.e7.
   PubMedGoogle Scholar
• Yang S-K, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–1242.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373.
   PubMed Web of Science ®Google Scholar
• Chiengthong K, Ittiwut C, Muensri S, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica. 2016;101(1):e24–e26.
   PubMedGoogle Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115.
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–539.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Hwang EH, Park JH, et al. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2016;28(4):4.
   Google Scholar
• Asada A, Nishida A, Shioya M, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2016;51(1):22–29.
   PubMed Web of Science ®Google Scholar
• Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16(3):280–285.
   PubMed Web of Science ®Google Scholar
• Nishii R, Moriyama T, Janke LJ, et al. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018;131(22):2466–2474.
   PubMedGoogle Scholar
• Moriyama T, Yang Y-L, Nishii R, et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood. 2017;130(10):1209–1212.
   PubMed Web of Science ®Google Scholar
• Ju HY, Lee JW, Cho HW, et al. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes. PLoS One. 2021;16(1):e0245667–e0245667.
   PubMedGoogle Scholar
• Bruneau JC, O’Marcaigh A, Smith OP. Pro-inflammatory and pro-coagulant properties of 6-thioguanine and 6-mercaptopurine: implications for their potential role in the development of sinusoidal obstruction syndrome. Leuk Lymphoma. 2010;51(1):164–167.
   PubMed Web of Science ®Google Scholar
• Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;368(9544):1339–1348.
   PubMed Web of Science ®Google Scholar
• Stork LC, Matloub Y, Broxson E, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the children’s oncology group CCG-1952 clinical trial. Blood. 2010;115(14):2740–2748.
   PubMedGoogle Scholar
• Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(1):100–102.
   PubMedGoogle Scholar
• Derijks LJJ, Gilissen LPL, De Boer NKH, et al. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: Dose or level dependent? J Hepatol. 2006;44(4):821–822.
   PubMedGoogle Scholar
• Weeramange CJ, Binns CM, Chen C, et al. Inhibition of UDP-glucose dehydrogenase by 6-thiopurine and its oxidative metabolites: Possible mechanism for its interaction within the bilirubin excretion pathway and 6TP associated liver toxicity. J Pharm Biomed Anal. 2018;151:106–115.
   PubMedGoogle Scholar
• Yoo YG, Na TY, Yang WK, et al. 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1α resulting in new vessel formation. Oncogene. 2007;26(26):3823–3834.
   PubMed Web of Science ®Google Scholar
• Pols TWH, Bonta PI, Pires NMM, et al. 6-Mercaptopurine inhibits atherosclerosis in apolipoprotein E*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol. 2010;30(8):1591–1597.
   PubMedGoogle Scholar
• Oancea I, Png CW, Das I, et al. A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity. Gut. 2013;62(4):594.
   PubMed Web of Science ®Google Scholar
• Toksvang LN, Schmidt MS, Arup S, et al. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review. PLoS One. 2019;14(5):e0212157–e0212157.
   PubMed Web of Science ®Google Scholar
• Escherich G, Richards S, Stork LC, et al. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia. 2011;25(6):953–959.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schaeffeler E, Möricke A, et al. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia. 2021. DOI:https://doi.org/10.1038/s41375-021-01203-7
   Google Scholar
• McAtee CL, Schneller N, Brackett J, et al. Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification. Cancer Chemother Pharmacol. 2017;80(6):1261–1264.
   PubMedGoogle Scholar
• Gruhn B, Brodt G, Mentzel H-J, et al. Two cases of veno-occlusive disease/sinusoidal obstruction syndrome after thioguanine treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2021;Publish Ahead of Print. DOI:https://doi.org/10.1097/MPH.0000000000002172
   Google Scholar
• Franca R, Rebora P, Bertorello N, et al. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J. 2017;17(1):4–10.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Pei D, et al. Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharmacol Ther. 2017;101(3):373–381.
   PubMed Web of Science ®Google Scholar
• Tamm R, Mägi R, Tremmel R, et al. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther. 2017;101(5):684–695.
   PubMed Web of Science ®Google Scholar
• Stocco G, Yang W, Crews KR, et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012;21(21):4793–4804.
   PubMed Web of Science ®Google Scholar
• Franca R, Stocco G, Favretto D, et al. PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenomics J. 2020;20(3):415–425.
   PubMedGoogle Scholar
• Smid A, Karas-Kuzelicki N, Jazbec J, et al. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016;6(1): 30244-30244. DOI:https://doi.org/10.1038/srep30244
   Google Scholar
• Zarou MM, Vazquez A, Vignir Helgason G. Folate metabolism: a re-emerging therapeutic target in haematological cancers. Leukemia. 2021;35(6):1539–1551.
   PubMedGoogle Scholar
• Zimdahl Kahlin A, Helander S, Wennerstrand P, et al. Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism. Basic Clin Pharmacol Toxicol. 2021;128(1):52–65.
   PubMedGoogle Scholar
• Liliemark J, Pettersson B, Peterson C. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro. Leuk Res. 1992;16(3):275–280.
   PubMedGoogle Scholar
• Milek M, Smid A, Tamm R, et al. Post-translational stabilization of thiopurine S-methyltransferase by S-adenosyl-l-methionine reveals regulation of TPMT*1 and *3C allozymes. Biochem Pharmacol. 2012;83(7):969–976.
   PubMed Web of Science ®Google Scholar
• Hareedy MS, El Desoky ES, Woillard J-B, et al. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119–1134.
   PubMed Web of Science ®Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–172.
   PubMed Web of Science ®Google Scholar
• Matimba A, Li F, Livshits A, et al. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics. 2014;15(4):433–447.
   PubMed Web of Science ®Google Scholar
• Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010;45(10):1014–1021.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Manabe A, Fukushima H, et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):380–384.
   PubMed Web of Science ®Google Scholar
• van Egmond R, Chin P, Zhang M, et al. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther. 2012;35(10):1181–1189.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Yang W, Smith C, et al. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2021;Publish Ahead of Print. DOI:https://doi.org/10.1097/FPC.0000000000000453
   Google Scholar
• Roberts RL, Wallace MC, Seinen ML, et al. Nonsynonymous polymorphism in guanine monophosphate synthetase is a risk factor for unfavorable thiopurine metabolite ratios in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(12):2606–2612.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Appell ML. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis. 2012;6(6):655–659.
   PubMed Web of Science ®Google Scholar
• Zimdahl Kahlin A, Helander S, Skoglund K, et al. Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden. Biochem Pharmacol. 2019;164:263–272.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Sanquer S, Loriot M-A, et al. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic–phenotypic correlation. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;773(2):119–127.
   PubMedGoogle Scholar
• Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-Methyltransferase: Molecular mechanisms and clinical importance. Pharmacology. 2000;61(3):136–146.
   PubMed Web of Science ®Google Scholar
• Wu F, Melis R, McMillin GA, et al. Retrospective data analysis of the influence of age and sex on TPMT activity and its phenotype–genotype correlation. J Appl Lab Med. 2019;3(5):827–838.
   PubMedGoogle Scholar
• Gibson J, Russ TC, Clarke T-K, et al. A meta-analysis of genome-wide association studies of epigenetic age acceleration. PLoS Genet. 2019;15(11):e1008104–e1008104.
   PubMed Web of Science ®Google Scholar
• De Boer NKH, van Bodegraven AA, de Graaf P, et al. Paradoxical elevated thiopurine S-Methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit. 2008;30:3.
   Google Scholar
• Lennard L, Chew TS, Lilleyman JS. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol. 2001;52(5):539–546.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Lennard L, Lilleyman JS. The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol. 1995;40(3):217–222.
   PubMedGoogle Scholar
• Ingelman-Sundberg M, Mkrtchian S, Zhou Y, et al. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1): 26-26. DOI:https://doi.org/10.1186/s40246-018-0157-3
   Google Scholar
• Zhou Y, Dagli Hernandez C, Lauschke VM. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. Br J Cancer. 2020;123(12):1782-1789.
   Google Scholar
• Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends Pharmacol Sci. 2016;37(2):85–86.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. How to consider rare genetic variants in personalized drug therapy. ClinPharmacol Ther. 2018;103(5):745–748.
   Google Scholar
• Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S -Methyltransferase gene locus. J Natl Cancer Inst. 1999;91(23):2001–2008.
   PubMedGoogle Scholar
• Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42(4):266–272.
   PubMedGoogle Scholar
• Lancaster D, Patel N, Lennard L, et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacology. 2002;50(1):33–36.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705–713.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children’s oncology group study. JAMA Oncol. 2015;1(3):287–295.
   PubMedGoogle Scholar
• Landier W, Hageman L, Chen Y, et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the children’s oncology group study AALL03N1. J Clin Oncol. 2017;35(15):1730–1736.
   PubMedGoogle Scholar
• Nielsen SN, Grell K, Nersting J, et al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol. 2017;18(4):515–524.
   PubMed Web of Science ®Google Scholar
• Larsen RH, Utke Rank C, Grell K, et al. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica. 2021. DOI:https://doi.org/10.3324/haematol.2020.278166
   Google Scholar